The UCL Cancer Institute is hosting a new series of Immunology Seminars aiming to showcase leading, cutting edge Immunology research to scientists across UCL and the Cancer institute.
The Cancer Institute has organised this seminar series with the specific goal of bringing together the immunology and cancer community in London in order to foster interaction, collaboration and to demonstrate, through cutting edge seminars, how the understanding of the basic principles governing the function of the immune system is fundamental to the development of novel and powerful cancer therapeutics.
In addition to meeting with Cancer Institute group leaders during the day, we have organised a “Lunch with the speaker” (for Postdocs and Students) to promote scientific discussion within our graduate and postdoctoral community.
Seminars will be held at 5 pm on the Courtyard Café of the Paul O’Gorman Building. A drinks reception will be held after each seminar.
Courtyard Café, Paul O’Gorman Building
Note in case of alternative venue, this is listed with the speaker
Wednesday 6th March 2013 – 4pm
NOTE VENUE: Leonin Price Lecture Theatre in the Institute of Child Health
"Engineering a clinically-appealing immune response to tumors and Pathogens"
Professor Laurence J.N. Cooperr Department of Immunology, The University of Texas, MD Anderson Cancer Center
BIO: Professor Laurence J.N. Cooper obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation (BMT) at the Fred Hutchinson cancer Research Center in Seattle. He joined M.D. Anderson Cancer Center in 2006 and currently leads the Pediatric Cell Therapy service (formally named the BMT program). In addition to caring for children, adolescents and young adults undergoing autologous and allogeneic hematopoietic stem-cell transplantation (HSCT), he runs a laboratory translating immunology into clinical practice. His program has multiple investigator-initiated trials that infuse T cells and NK cells to target malignancies. The adoptive transfer of lymphocytes represents the future of HSCT as he and other investigators enhance the potency of the immune system to eliminate residual cancers.
19th June 2013 – 5pm
Professor Facundo Batista
London Research Institute,
Cancer Research UK
Sergio Quezada (email@example.com)
Please contact Dr. Bennett or Dr. Quezada if you want to meet with the speakers .